Humanigen Inc (CE) (HGEN) Quote

https://share.newsbreak.com/6vvtpug5

https://share.newsbreak.com/6vtipmmh NEW VARIANT SPREADING

The important thing is that you got a green checkmark, instead of the signature shit-faced (have you seen his profile pic, very appropriate) 💩🤡 emojis you got for a previous post. Good job!

sanofi is no longer a shareholder.
In Sweden, all public companies have list of shareholders in public view.
Right now even in Bankruptcy, the court and nobody knows who actually owns hgenq? there is only list of people who filed to complain and they can get that .047/share lawsuit. those are the former disgruntled shareholders before hgenq filed for bankruptcy and is the last in line to get anything in bankruptcy court. if the fake creditor commitee who claim to be ripped out of 44 million don't get a dime, what makes you think peon shareholders will get anything? shareholders are not liable for any crimes or liabilities of the company or management.

https://share.newsbreak.com/6vefr7bz
MERS COV2 in Saudi Arabia 🇸🇦

"What would it take to monetize these Milestone Events? It would take receiving a BLA from the FDA for CMML, and related indications in the US. I think Sanofi, with their deep pipeline of oncology products and processes, would be an excellent partner for us in oncology, once they complete the spin-off of their healthcare division in the coming months."

Sanofi, one of Humanigen's first shareholders, issued four Press Releases in between April 17th - May 2nd, 2024.

https://www.sec.gov/Archives/edgar/data/1121404/000119312524129331/d793882d6k.htm

And as we know, Sanofi is planning to spin-off their healthcare division. So, a lot going on there. Did they overlook something?

"Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines
May 10, 2024

>Agreement provides individuals with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwards
>Provides Novavax with cash and an equity investment totalling approximately $1.2 billion (upfront payment of $500 million and up to $700 million in additional development, regulatory and launch milestones), plus tiered royalties
>Novavax is entitled to additional launch and sales milestone opportunities of up to $200 million, plus mid-single digit royalties, for each additional Sanofi vaccine product developed under a non-exclusive license with Novavax's Matrix-M™ adjuvant technology
>Accelerates potential for development of a novel COVID-19-Influenza combination product based on authorized vaccines with demonstrated efficacy and tolerability, potentially offering individuals enhanced convenience and protection"

https://ir.novavax.com/press-releases/2024-05-10-Novavax-and-Sanofi-Announce-Co-exclusive-Licensing-Agreement-to-Co-commercialize-COVID-19-Vaccine-and-Develop-Novel-COVID-19-Influenza-Combination-Vaccines

These developments have enabled Novavax to remove their 'going concern' warning. "Liquidity and Going Concern
The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern within one year after the date that the financial statements are issued and contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business."

see pg 7
https://www.sec.gov/ix?doc=/Archives/edgar/data/1000694/000100069424000031/nvax-20240331.htm

I'm hoping for news this week that Humanigen's patented methodology was used to enhance Nuvaxovid, and that we will see our restructuring completed with a discharged CH11, and some type of licensing, partnering, or a business combination announced.

if stolen property is traded many times does the person who it was originally stolen from it still claim it.? that is a legal question. it's not theirs if they know it was stolen or if the asset has a lien on it. even if the paid fair value but the asset was purchase it has a lient on it, it's not really there that is why nobody wanted to bid on the hot assets. it's like buying a used car that has lien on it or creditor lien on it. if you buy stolen property not only do you lose the stolen asset you paid for, you also lose the money you use to buy the stolen or hot asset that has a lien on it. but US gov't has proven it may not be the case of stolen Russian assets and think they can sell stolen private property and sell it to pay for ukraine war.
it's grey area in legal world. whether the US gov't or any person can 'steal' assets and sell it. and the buyer doesn't really own it. because the property was stolen it doesn't matter if the gov't stole it or anyone who stole it. if someone has a claim on it, an dasset is hot, any buyer risk losing the asset and losing the amount they paid for the stolen property.

The only legal argument or csse or dispute hgenq equity owners have is whether the assets were sold at below market value or was not sold at 'FAIR MARKET VALUE' in a closed auction which nobody was allowed to bid and restricted auction. the auction was setup that nobody in their right mind would bid on it and most buyers would rather pay 'fair value' than buy assets in a fire sale that is disputed and has ligitation on it. If a buyer buys from taran then that is hgenq shareholders cannot sue the buyer who bought it from taran if taran sold the assets at 'fair market value' even if taran bought it for free. or if it was stolen. property

I'm not questioning whether LENZI has value or not. It probably has value because if hgenq had no assets taran would not waste time or $2 million to buy the 'assets' for free.
In many biotech startup with only stage 1, they have no value and only 2-4 employees. and if they go bankrupt there is no auction to sell as there is nothing sell. they just liquidate and shut down the business.
and file a corporate dissolution with the corporate registry. Any unsecured creditors are left holding the losses as a write off loans or dead accounts receivables. there is no court hearings no creditor committee as these companies have no assets to seize other than some furniture in some shared office.

Unless Dale lost his Appeal, Humanigen is positioned to enter into a stock-for-stock merger with Taran. If Dale lost his Appeal, Taran could just outright buy Humanigen's shares. I don't think it's likely that Dale lost his Appeal, or Durrant would have submitted a Tender Offer, instead of an Asset Purchase Agreement.

You're not recognizing the value of Humanigen owning ~90% of the shares they issued, leaving a float of 192% of our OS. If lenz is gaining market access, whether through authorization or approval, or through its IND use by Gracell and Novavax, that news, announced with the Taran merger, will be the trigger for Humanigen to recall their loaned shares.

the $5 million legal fees hgen the corporation spent on this case or lawsuits is not for legal expense, the money was to pay off the SEC, pay off the FDA, pay of the Judges etc. to ignore the stock scam or robbery. and walk free.

taran or the owner of taran is also the 90% owner of hgenq shares or the controlling shareholder of hgenq. that is why hgenq didn't object to selling taran lenzi ip for nothing.
main reason no bids from other pharma companies, they usually don't bid on assets with a lien on it, which was the promissory not to hgeneq shareholders.
if the hgenq shares are dissolved and liquidated, taran no longer owes hgenq shareholders anything and the promissory not is void and invalid if the company no longer exist. a dead money has no legal status in the courts and can no longer sue taran. if the company is liquidated and dissolved
any lawsuit by former hgenq shareholders would be a separate civil case which takes years and may not have a case. and case denied by omnibus hearing. there is no case for hgenq shareholders to sue taran. you have the courts and SEC working against minority hgenq shareholders you cannot sue them and basically screwed. legally the controlling shareholder of hgenq sold assets for nothing. to taran or himself. these guys know the legal system to screw shareholders in this stock scam, they got everything paid off , you know what I mean.

taran didn't even have to give hgenq shreholders anything or that schmuck insurance or the promissory not. legally, the fake creditors committee owns the company. technically. it's like that fake baloney lawsuit the guilliani was sued for 'defamation ' for llike $100 million and he declares bankruptcy so he doesn't have to pay a dime of that lawsuit. same with Trumps conviction of 'rape' there is no rape. it was consensual sex and stormy daniels was an escort. there is no shame what Trump did, who cares if Trump as 5 mistresses they were consenting and willing females. back in the good old days, rich guys like Trump would have 5 wives, nine lives, alright. mormons can have 10 wives but the gov't banned polygamy like its some kind of 'crime' the status of man was how many wives he had..but gov't banned it.

At this moment based on the legal facts. shareholders own no assets and even the promissory not of payment to hgenq shareholders can be voided if the shares are liquidated and dissolved. to get any money from taran, shareholders would have to file another civil case against taran, in a civil case. taran legally doesn't owe hgenq any compensation with the stolen ip asset they paid nothing for. but that is for juror to decide, the chapter 11 court or judge doesn't care about civil case or criminality charges by the SEC, it's not his job but based on chapter 11 processes, technically, the assets are sold and hgenq shareholder no longer own the ip lenzi patents and entitled to nothing. and no compensation based on chapter 11 law.

That really does promise to be good news for Taran and Durrant!

But, it would be far better for them to trade Taran shares for Humanigen shares, as I think they will. It makes no sense for Taran to deal themselves out of the recall of Humanigen's shares. I hope Durrant announces the stock-for-stock merger now.

Sounds like more great news for Taran and Durrant if Lenz is involved.

"Novavax shares soar on license deal with Sanofi at lofty valuation
By Sriparna Roy
May 10, 2024"

https://www.reuters.com/business/healthcare-pharmaceuticals/frances-sanofi-covid-19-vaccine-deal-with-novavax-statement-2024-05-10/

I am obviously very happy about this announcement, as these two companies have been the subjects of several of my posts. Now if we could only confirm that the efficacy of the Novavax vaccine was indeed enhanced by Humanigen's patented methodology.

Lenzilumab's sabotage was done by the design of the NIAID/NIH ACTIV-5 clinical trial. All the while, billions of Genetically Modified Organisms (GMO's, aka 'vaccines,') were administered to the populations mainly of the US, the UK, and Australia. mRNA vaccines were not administered in China.

Lenz will gain market access through it's ability to prevent CMML, and to enhance CAR-T and protein-based covid vaccines.

it's because big pharma doesn't want 'cheap' drugs that compete with their advance synthetic drugs to treat viral infections. Lenzi is probably cheap to make since it's may be from natural sources and don't need expensive lab to manufacture. where as natural remedies are much cheaper to make. It business, it's called shutting the competition either buy buying them out to prevent cheaper alternative 'competition.' leniz probably has side effects like all drugs or not as effective as other drugs. lots of drugs does the same thing as Lenzi which is treat an virual infection or treat people with blood diseases. or blood disorders. people with AIDS used to die or death sentence in the 1980's but with these expensive Aids anti-viral cocktails where a patient takes multiple drugs to replicate a person immune system, a person like magic johnson can live with aids like long term disease and don't die from Aids anymore if they take the cocktail of expensive anti-viral drugs. like a cocktail it only works if you take multiple drugs like mixing two colors to get one color

Lenzi type of medicine is derived from natural sources? could be blood from another animal, Drinking blood has been known for centuries to cure a lot diseases. like smoking magic mushrooms to cure alcoholism and mental illness and chewing cocoa (cocaine') leaves to reduce depression side effects are some people go insane taking magic mushrooms and get addicted and violent snorting cocaine but it works. and works. big pharma prevents the public to access 'natural remedies' via the FDA gov't telling the public what drug they can have accesss to..This almost unconstitutional what the FDA and gov't is doing.
Either the FDA is deliberating not approving it of humanigen deliberatedly sabotage it's FDA application not approved due to 'technicalities' in statistical variations.

I don't care whether it was the covid trial, or the CMML study, seasoned clinical trial investigators were SHOCKED by how quickly, safely, and effectively lenz saved the lives of severely ill patients. I'm specifically talking about Mayo Clinic's Dr. Claudia Libertin, in the video-taped trial review meeting with fellow investigators on the covid LIVE-AIR trial, as well as Dr. Daniel Thomas, Clinical Hematologist, Royal Adelaide Hospital, Associate Professor, Adelaide Medical School, The University of Adelaide, who presented the interim results of the CMML study.

https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00494-X/fulltext (I can't access the video archive)

https://medicalresearch.com/cancer-_-oncology/preach-m-trial-humanigen-study-evaluates-lenzilumab-and-azacitidine-for-cmml/#:~:text=The%20preliminary%20results%20from%20the,cells%20with%20RAS%2Dpathway%20mutations.

Lenz is practically miraculous. That was evidenced by the reactions of the clinical trial investigators (no, there are not "lots of drugs" that cause those reactions from the investigators) , and confirmed by both the Lancet and Thorax peer-reviews.

So yes, lenz works. Will lenz be approved? Yes, by necessity only. Regulators have a vested interest in saving the covid market for Pfizer and Moderna, and for their share of royalties from the approval of these products.

"However, in our breaking investigation, we found hundreds of millions of dollars in payments also flow the other way. These are royalty payments from third-party payers (think pharmaceutical companies) back to the NIH and individual NIH scientists."

NOTE: I do NOT advocate for Fauci's assassination.

https://www.sammyboy.com/threads/fauci%E2%80%99s-royalties-and-the-350-million-royalty-payment-stream-hidden-by-nih.321335/

Management is ALL about getting regulatory approval, even if overseas, and saving patients' lives, as well as rewarding shareholders.

Chapter 11 courts are not real courts but rather administrative processes.
If this was a real court case where you had jurors and judges for criminal case
Charge: Larceny
larceny: theft of personal property.
Where the conviction is determined by 10 jurors, someone is guilty and going to jail. but not in fake court trials like chapter 11 where there is no interviewing the person charged, no verify fake evidence and claims. nothing is taking as real in a real court. Even the people educational claims is investigated to be true or not. bank accounts are interviewed. etc. but chapter its more of administrative and due to low priority crime, bankruptcy fraud is not a top priority.

There so many of these biotech companies with zero revenue other than research and development of new drugs.

As for LENZI, it's been researched and developed for clinical trial since 2015.

If the FDA is costing drug companies that much money to get approval it increases cost of health care. Either the drug works or not.

1. Why is Lenzi not approved
2. Will Lenzi ever be approved
All these biotech with zero sales and unapproved drugs rely on investors to keep the business operating. Even with only 4 employees it cost annual burn rate is 5 million.
However a lot of these biotech firms was not about getting FDA approval or getting the drug to commercialization. The entire plan was to sell to investors and then go bankrupt and not raise additional shares. HGEN could have easily raised additional investement if it was not for the legal liabilities and shareholder lawsuit which was like near 40 million. It cannot get any investor to put money into the company but that was the plan to declare chapter 11 and auction the ip asset for nothing. and start another biotech company and sell hopium to new investors again. But in the process, the drug itself is not sold to the public for use due to no FDA approval even if the drug does have efficacy and works. There are probably lots of drugs like lenzi that does the same thing in immune boosting drugs. The same reason Dracula drank human blood to cure his blood cancer or some kind of blood disease.

"...the rich live and poor die because they cannot afford the anti-viral drugs. FDA would not approve these drugs."

Actually, we ARE seeing a change in the FDA's view towards drugs like lenzilumab.

I mentioned previously that Invivyd received an EUA for PEMGARDA™ (pemivibart) for pre-exposure prophylaxis (PrEP) of COVID-19 in certain immunocompromised people and was aligned in principle with the FDA. "The immunobridging pathway for COVID-19 treatment is enabled by data from the Phase 2/3 clinical trial (STAMP) of adintrevimab, the prototype monoclonal antibody (mAb), for the treatment of COVID-191 and data from the ongoing CANOPY Phase 3 clinical trial of pemivibart for PrEP of COVID-19. The potential COVID-19 treatment EUA request would focus on the critical treatment needs of people in the U.S. who have moderate-to-severe immune compromise and for whom alternative COVID-19 treatment options are not clinically appropriate or accessible. "

https://www.globenewswire.com/news-release/2024/05/07/2876606/0/en/Invivyd-to-Pursue-Rapid-Immunobridging-Pathway-to-Potential-EUA-for-Treatment-of-COVID-19-in-Moderately-to-Severely-Immunocompromised-People-Based-on-U-S-FDA-Feedback.html

I think this change simply reflects the FDA's recognition that having no viable treatment therapeutic for covid 19 is untenable.

Equally untenable is failure to utilize lenz to enhance non-mRNA vaccines. The EU challenged, but then quickly accepted the enhanced performance results of the latest Novavax covid vaccine. But Novavax is, rightfully, also under investor pressure to capitalize on this opportunity.

"Shah Capital Launches Campaign Urging Stockholders to Vote AGAINST the Re-Election of All of Novavax’s Directors Up for Election at its 2024 Annual Meeting"

https://www.sec.gov/Archives/edgar/data/1000694/000092189524001044/dfan14a11882nvax_05062024.htm

Not yet

Is there good news for HGEN?

the reality was most of the deaths were people who were NOT vaccinated. when is spread like wildfire. a large percentage of people have weak immune systems and if they had access to drugs like Lenzi they may have lived and not died. or any other anti-viral drug which is very expensive. if they had access to expensive drugs they would not have died from the corvid virus. so money can buy you health. and the rich live and poor die because they cannot afford the anti-viral drugs. FDA would not approve these drugs. and only for compassionate use meaning death is the result if no other drug is use

the mRNA vaccine was experimental drug that would no be approved by any gov't drug regulator under regular drug approval process, ie it was an emergency drug or compassionate use. the risk is death if this can cure you, you take it right....so that was what happened. the virus was causing over 2 million dead. and drugs like Lenzi were after the fact you got infected drugs, to cure the symptoms. or help your body defend itself for people who were not vacccinated, as most of the deaths were from people who were not vaccinated.

"There's roughly 4,000 papers showing vaccine complications and deaths" noted Dr. McCullough, "What we're seeing is just the tip of the iceberg, it's a giant human experiment. We can't possibly know what's going to happen because things weren't properly researched ahead of time."

oh my

The earliest patent application for developing humanized antibodies was filed in 2015. The patent was granted to Humanigen in 2021.

More recently, another patent was filed in 2018, and granted to Humanigen in 2020. The following month, another patent was granted for CAR-T use. There were other patent grants, as well.

So it appears lenz has met your requirement of, "...any new drug needs at least 5-10 years of data," based on the 2015 and 2018 patent filings, which were granted.

Lenz wasn't in a Phase III trial, it had completed it, and successfully met the primary endpoint. I normally provide links, but you have shown me that such substantiation means nothing to you.

Lenz was sold to whom "for nothing?" Our CEO. And we know that preparations have been made for Taran to issue stock. Why? For a stock-for-stock merger?

I agree that lenz has multiple use applications. I consider it like WD-40, but I like your analogy to baking soda, as well.

And I know you realize that neither Pfizer, Moderna, nor mRNA technology have as much data history that lenz has, but they are authorized.

And perhaps you further realize that the mRNA vaccines are CAUSING injuries and excess deaths?

But Humanigen's success is on the horizon.

it seems like you want to promote this penny stock? it's has no hope. you cannot pump dead stock. there is no hope in this stock. most of these penny stock, you selling hope. or selling hopium. there is no hope in this company its already bankrupt, and soon dissolved and liquidated and delisted. you cannot pump a dead horse. that is already dead. hopeless.

lenzi was in STAGE 3 one step before FDA approval or any regulatory approval. I don't doubt the efficacy of the 'molecule' any new drug needs at least 5-10 years of datat to get commercialization for any side effects. but the problem hgenq shareholders don't own the LENZI patent, it's been sold for nothing. even some drugs with stage 1 has more larger market cap of 100 million. just on potential. or speculation it might get approval. lenzi was originally a drug for hemo diseases but somehow had applications to treat corvid immune response treatment. it's like baking soda with multiple uses. 1. cleaning. 2. deodoriant. 3. cooking.

At last report, Humanigen had several sponsored clinical trials of lenzilumab in progress.

"The Company is developing lenzilumab in chronic myelomonocytic leukemia (“CMML”), a rare blood cancer, for which the Precision Approach to Chronic Myelomonocytic Leukemia (“PREACH-M”) study is underway, and is continuing its plans for the Risk Adapted Therapy in Acute GvHD (“RATinG”) study in acute graft versus host disease (“aGvHD”) that occurs in patients undergoing bone marrow transplant, as these studies are majority funded by its partners."

In addition, we have the following. Mayo Clinic, whose trial investigators led Humanigen's successful LIVE-AIR trial for the treatment of hospitalized and hypoxic covid patients, is also conducting an Investigator Initiated Trial..."of lenzilumab in combination with CAR-T therapies. We are also developing iFab, an EpAh-3 targeted monoclonal antibody, currently in Phase 1 development, as part of an antibody drug conjugate (“ADC”), for certain solid tumors."

see pg 14
https://www.sec.gov/ix?doc=/Archives/edgar/data/1293310/000121465923007002/hgen-20230331.htm

More on Mayo Clinic's CAR-T program can be found here, which includes a 7 minute video.

https://www.mayoclinic.org/departments-centers/car-t-cell-therapy-program/home/orc-20404317

None of the above is speculative. In addition, we know that the interim analysis of the PREACH-M trial showed outstanding results for CMML.

"The additional data demonstrate that in all 10 participants with at least three months of treatment with both lenzilumab and azacitidine, blood monocyte count decreased fivefold (P=0.03), the percentage of blast cells and pro-monocytes decreased more than twofold (P=0.04), and C-reactive protein decreased more than threefold (P=NS) with improvements noted after both 3 months and 6 months of this combination treatment. These results suggest lenzilumab may normalize hematologic and inflammatory aberrations in CMML and improve the condition of participants. All ten evaluable participants had a rapid clinical response."

https://ir.humanigen.com/English/news/news-details/2023/Humanigen-Presents-Promising-New-Hematologic-Data-from-PREACH-M-Trial-for-Chronic-Myelomonocytic-Leukemia-Treatment-at-the-2023-European-Hematology-Association-Congress/default.aspx

Also, Mayo Clinic's Dr. Zelalem Temesgen also led Humanigen's effort to establish CRP as a biomarker, to identify which covid patients would benefit the most by being treated with lenz. The Thorax peer review of those results confirmed the following. "Exploratory analysis for the effect of lenzilumab on SWOV was conducted by the CRP baseline quartile. Response to lenzilumab was observed in the first through third quartiles of baseline CRP with the greatest lenzilumab treatment effect observed in the first quartile (CRP <41 mg/L; HR: 8.20; 95% CI 1.74 to 38.69; p=0.0079)..."

https://thorax.bmj.com/content/78/6/606

Those are facts which should have forced regulatory authorization or approval. Instead, the FDA conducted a study of late-stage patients, beyond the treatment scope management intended, and failed to meet the primary endpoint in that trial, which the class action lawyers negligently used as the basis for their suit against the company.

Regardless, I am looking forward to seeing if lenz is being used by Novavax to enhance their covid vaccine. On October 15th of last year, the EU delayed approval of the vaccine. "The Financial Times, which first reported the news, said the EMA had questions on the potency of the vaccine's latest version, and that it is seeking to ensure its characteristics will be the same across different production sites."

https://www.reuters.com/business/healthcare-pharmaceuticals/eu-delays-approval-novavaxs-revised-covid-vaccine-ft-2023-10-15/

By the end of the month, the EU approved the vaccine.

"Novavax's Updated COVID-19 Vaccine Now Approved in the EU
October 31, 2023...

Approval was based on non-clinical data showing that Novavax's updated COVID-19 vaccine induced functional immune responses against XBB.1.5, XBB.1.16 and XBB.2.3 variants. Additional non-clinical data demonstrated that Novavax's vaccine induced neutralizing antibody responses to newly emerging subvariants BA.2.86, EG.5.1 FL.1.5.1 and XBB.1.16.6 as well as CD4+ polyfunctional cellular (T-cell) responses against EG.5.1 and XBB.1.16.6. These data indicate Novavax's vaccine can stimulate both arms of the immune system and may induce a broad response against circulating variants."

https://ir.novavax.com/press-releases/2023-10-31-Novavaxs-Updated-COVID-19-Vaccine-Now-Approved-in-the-EU

What better vaccine enhancement than lenz could have so quickly caused the 180 by the EU, for multiple variants, and imbued a T cell response with a high level of potency and dependable replication?

For that matter, will Mayo discover similar increases in lenziulmab's safety and efficacy in their ITT for CAR-T, as Gracell may have? And will Mayo, as well as Sanofi, find success in using Ifab as an antibody drug conjugate (ADC) in their cancer tumor treatment programs?

Humanigen has never been stronger than we are now, and we have never been closer to success. Incredible performance and execution by management.

State of delaware is where corporations are put on trial for bankruptcy. the bankruptcy case is closing and this omnibus is pre-trial for a civil case or criminal case. civil case only penalty of found guilty of any wrong doing or fraud is just a fine. whereas in criminal case corporate embezzlement or wire fraud , any conviction is jail in prison with gangsters in prison. hard time. Don't believe the garbage that prisons have tennis courts and recreational activity for inmates.

You're very welcome, eb. But my explanation is actually quite sanitized, with an underlying deep and dangerous tale relating to serious criminal activity. I fully understand why management designed our share structure as they did, to mask their accumulation of shares. And I wanted to highlight DJT's experience recalling their loaned shares, to illustrate the importance of excellent news (regulatory approval, restructuring) to add share price momentum to our next recall. I saw some activity that suggests to me that Humanigen could be ready to proceed with executing their game plan. At least, I really hope that's what it means. It could just mean that there is a new normal, which would be fine, if this signals starting our new beginning.

By the way, without the approval of the Emergency Rule Change, the US equity market would have crashed in three days.

Appreciate that explanation, Jay.

why would anyone bid $2 million as stalking bid if the ip patents were worthless. in chapter 7 and chapter 11 in regular business bankruptcy there is no stalking bid. assets are seized by the receiver appointed by the bankruptcy court and auctioned off in an 'OPEN AUCTION' and business is shutdown.

the value of ip or intellectual property is what revenue it can generate. the ip itself has no value if it cannt generate revenue or life of the ip asset. most patents last only 20 years. which is why drugs are so expensive once it's approved. the ip owner has to recoup his cost and expense in developing the 'technology;
as for lenzi it was already making 2.5 million in licensing from just one countrry in australi and was not even approved for commercializiation if the drug was approved for commercialization . global sales can reach 1 billion. so taran got the ip which can possibly generate 1 billion in net cash for nothing.

the entity that owns taran or the controlling shareholder is probably the same entity that owns hgenq or the controlling shareholder of hgenq. which is how taran bough the lenzi ip patents for nothing or free because nobody gives something for nothing 🤑

why is there still 4 employees still on the payroll? in regulator chapter 11 or chapter 7, everybody is fired and an insolvency accounting bankruptcy firm takes control of the company books. and bankruptcy is easily completed. with no objections

Based on what I know, these .047/share settlement was before the chapter 11 petition. and the objections by the equity of the debtors didn't get paid for the .047/share settlement and the law firm probably may not have received the $3 million which was settled. hence the equity debtors. these were probably the equity interest who filed to the get .047/share claim as shareholders. in the lawsuit. but since there is no money after liquidation and dissolution of the hgenq corporation, what is the point of the omnibus hearing.?

Ominbus hearing on June 13. Omnibus hearing is pre-trial to determine if there is enough evidence for criminal trial. didn't know there were that many small peon shareholders who object to this sham chapter 11 robbery of assets. Most had less than $5000 invested in this stock scam, the biggest and few had over $25,000 and thought it was a legit investment opportunity and invested over $50,000 in this stock fraud operation like the hundreds of other listed stocks. Lenzi is a real asset but the chapter 11 petition was the scheme and the plan. to embezzle assets with fake creditor 'disputed' claims.

Who does Henry work for. he is just an employee. why are the 4 employees not fired and still getting paid $20,000/month for doing nothing.

There is no business to manage. you don't need the board of directors, no ceo nor you need any CFO. the company is done.

One of Sanofi's three new independent Directors is John Sundy. "Between 2014 and 2021, he held several management positions including Senior Vice President at Gilead Sciences..."

https://www.sanofi.com/en/media-room/press-releases/2024/2024-02-22-18-02-50-2833994

Sundy's tenure at Gilead was during the time of our collaboration with them.

"Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (Axicabtagene Ciloleucel) with Lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
-- Phase 1/2 Multi-Center Clinical Trial to Begin Enrolling in Q4 2019 --

The objective of this study is to determine the effect of lenzilumab on the safety of Yescarta. Kite will act as the sponsor of this study and will be responsible for its conduct."

https://www.gilead.com/news-and-press/press-room/press-releases/2019/5/kite-and-humanigen-announce-clinical-collaboration-to-evaluate-investigational-combination-of-yescarta-axicabtagene-ciloleucel-with-lenzilumab-in-r

As I recall, Humanigen refused to sign an exclusivity agreement for Gilead's use of lenz, so Gilead ended up buying Forty Seven for $4.9B, only to have to suspend patient enrollment in a clinical trial due to lack of magrolimab's efficacy.

https://www.gilead.com/news-and-press/press-room/press-releases/2020/3/gilead-to-acquire-forty-seven-for-49-billion

https://www.biospace.com/article/gilead-suspends-patient-enrollment-for-troubled-magrolimab-in-solid-tumor-trials/#:~:text=In%20July%202023%2C%20Gilead%20announced,satisfied%20the%20criteria%20for%20futility.

I could get into Sanofi's agreement with AstraZeneca, who acquired our former board member Kevin Xie's Gracell, but you guys can look into it if you're interested.

Restructurings sure can get complicated.

Some things never change, shajelly. Crucial to our success is Humanigen's plan to recall their loaned shares, which we see that Trump Media (DJT ticker) attempted in a completely amateurish fashion.

The problem comes exactly from my effort to focus on Penson Financial for their role in the SpongeTech market, which led to an Emergency Rule Change the SEC had to approve to transfer Penson's accounts to Apex Clearing.

"I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change

The Exchange proposes to temporarily suspend the requirements of Exchange Rule 2.6 and related Exchange rules concerning the approval of new Members?[3] of the Exchange in order to approve Apex Clearing Corporation, f/k/a Ridge Clearing and Outsourcing Solutions, Inc. (“Apex Clearing”) as an Exchange Member, subject to Apex Clearing complying with Exchange Rules for a new Member within 30 calendar days of the date that Apex Clearing is provisionally approved as an Exchange Member. The Exchange is also proposing to accept Apex Clearing's assumption of all of the existing clearing agreements and arrangements currently in effect between Penson Financial Services Inc. (“PFSI”) and various other Exchange Members by execution of a global agreement thereto."

https://www.federalregister.gov/documents/2012/06/11/2012-14072/self-regulatory-organizations-bats-exchange-inc-notice-of-filing-and-immediate-effectiveness-of-a

On the plus side for Trump Media, they do have people who understand what is happening, at least to an appreciable extent.

"“I believe quick action is necessary to protect retail shareholders, identify wrongdoers, and determine whether any laws including [Racketeer Influenced and Corrupt Organizations Act] statutes and tax evasion laws have been violated,” wrote CEO Devin Nunes, who on April 24 first asked top House Republicans to probe short selling of Trump Media stock.

Nunes, in a letter dated Wednesday, wrote that the committees should seek documents and testimony from the eight firms that he named: Apex Clearing, Clear Street, Cobra Trading, Cowen and Company, Curvature Securities, StoneX Securities, TradePro and Velocity Clearing."

https://www.cnbc.com/2024/05/02/djt-trump-media-ids-firms-for-house-short-selling-probe.html

My question is, does Nunes know that the House members he is asking for quick action, may be rightfully included as RICO defendants? They empowered Apex Clearing by the Emergency Rule Change they approved.

These are the minefields that Humanigen's management have to contend with. They did so successfully as Kalobios, and they are even better positioned to succeed now.

"Shareholders would have been better off continuing to collect short interest, as DJT dropped 9.6% today."

How does a shareholder "collect short interest'????

people who own 50 shares of a company with 200 million shares don't matter. and you don't own the company. the company currently has less than 20 shareholders. and if you have less than 50 shareholders it is a private company. essentially the company is a private company with less than 20 shareholders and one shareholder owning 90% of the shares. waste of money sending mailing to peon shareholders to vote when one guy decides who is the board of directors. in many companies, the board of directors is selected by the ceo who is an employee. like this company, the ceo is also the chairman of t he board, yet on paper he owns less than 200,000 shares but controls and owns the company. something wrong with the corporate structure. in this company, the ceo and three board of directors is just a front for the real owners of hgenq and many companies listed in the exchange. you have one guy who sits on 10 board of directors and has a full time job. how can he do his duties as a board of directors. and gets paid $100,000/year for seat as board of director that only meets 4 times a year

the hgenq 'corporation' is being dissolved which was not part of the initial chapter 11 application. but is always the case. new company emerges with new shares. either your old shares are worthless or traded for new shares that. the controlling shareholder don't need the minority shareholder vote or permissions to dissolve the company

these billings don't need the judge approval either. it's so the lawyers can make money filing the forms. and for documentation only. you don't even need to be a lawyer to be in court and company can represent themselves. the company spent over 5 million in legal fees on their books in the last 3 years. As for the company ,its being liquidated, and dissolved. A new company, with new shares. as how much existing shareholders of the hgenq will get in new company that is the question. nothing. or shares bought out so end any litigation. issues with former investors or shareholders.

the 'loaned shares' what are you talking about on the OTC there is only 38,000 shares short and still not covered which mostly the market maker of this stock, nakes short positions by market makers or the broker/dealer don't have to cover if the shares are worthless unlike retail traders, if retail trader has short position they have to cover and pay borrowing fee. market makers don't pay any borrowing fees in naked shorting. naked shares shorted are not even in the shares shorted info.

"and you need to let the judge know how much you are billing the clients."

Why bother? In your same post, you said, "...hgenq owns no assets." If so, then you're saying the judge is too dumb to convert the case to a CH7, which he should do, if Humanigen is worthless.

But not only do we see the CH11 continued, we see just the opposite of a 'worthless' determination of Humanigen's value. We see additional value recognized.

"The settlement amended the APA to, among other things, significantly expand the events that will trigger the contingent “Milestone Payments” and increase the amount of those payments under the APA."

I think the company owns about 90% of the shares they have issued, and subsequently loaned. And just like shares investors are holding, the price of those shares will spike considerably when Milestone Events are reached, and we advance our restructuring, in conjunction with a recall of our loaned shares.

I have no relationship with the company or insiders, and I don't post for pay. Millions of preventable deaths, and millions more excess deaths, can be avoided when lenz is used as a vaccine enhancement, or as a therapeutic in lieu of 3+ mRNA jabs. The insiders, the judge, and the creditors know more than we do, and they seem to be seeing increased value, as do I.